Slingshot members are tracking this event:

Moleculin (MBRX) Announces Interim Results in Pediatric Brain Tumor Phase 1 Clinical Trial

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details The first three patients in the trial received treatment at a dose level of 4 mg/kg with no adverse events related to WP1066 and the study will now proceed to the next higher dose of 6 mg/kg.  One of these patients with diffuse intrinsic pontine glioma (DIPG), showed an apparent response to the treatment with both clinical improvement and radiologic reduction of tumor size.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 01, 2020
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Pediatric Brain Tumor, Phase 1 Data